scholarly journals Vancomycin or Daptomycin for Outpatient Parenteral Antibiotic Therapy: Does It Make a Difference in Patient Satisfaction?

2021 ◽  
Vol 8 (8) ◽  
Author(s):  
Katherine H Wu ◽  
George Sakoulas ◽  
Matthew Geriak
Keyword(s):  
Patient Satisfaction ◽  
Antibiotic Therapy ◽  
Antimicrobial Therapy ◽  
Telephone Survey ◽  
Satisfaction Score ◽  
Parenteral Antibiotic ◽  
Outpatient Parenteral Antimicrobial Therapy ◽  
Outpatient Parenteral Antibiotic Therapy ◽  
Interference Score

Abstract A 5-question telephone survey was administered to compare satisfaction between patients receiving vancomycin vs daptomycin outpatient parenteral antimicrobial therapy (OPAT). Twenty-seven patients completed the survey (40%). Vancomycin had higher daily interference score than daptomycin (P = .03). All patients receiving daptomycin reported a satisfaction score ≥8/10, as compared to 67% of patients who received vancomycin (P < .03). OPAT antibiotics with less cumbersome administration regimens may translate into higher patient satisfaction and quicker return to life normalcy.

scholarly journals P64 Implementation of a paediatric outpatient parenteral antibiotic therapy (p-OPAT) service at a specialist children’s hospital

2020 ◽  
Vol 105 (9) ◽  
pp. e39.2-e40
Author(s):  
Hannah Porter ◽  
Kate Stock
Keyword(s):  
Data Collection ◽  
Antibiotic Therapy ◽  
Antimicrobial Stewardship ◽  
Antimicrobial Therapy ◽  
List Type ◽  
Parenteral Antibiotic ◽  
Outpatient Parenteral Antimicrobial Therapy ◽  
Paediatric Outpatient ◽  
Bed Days ◽  
One Year

AimThe aim of this project is to optimise patient care, enhance patient experience, improve antimicrobial stewardship and assist patient flow through the hospital.MethodData collection was conducted one day a week over five consecutive weeks. All eligible wards were visited. Patient medication charts were inspected to see if intravenous antimicrobials were prescribed and a patient - specific data collection form was then completed. All the patients that met the eligibility criteria to be put forward for OPAT referral were then considered from a clinical perspective by a paediatric consultant as to their suitability for OPAT or IVOST and discharge. If the patient was deemed suitable for an OPAT discharge or IVOST and discharge a decision was made as to what antimicrobials they would theoretically have been on when discharged home. The number of potential bed days saved was calculated as the number of days between the patients review by the consultant (ie the day of data collection) and the date of their discharge prescription from that episode of care.The following was examinedpercentage of patients with identified pathogenspercentage of patients that had received input from the ID teampercentage of patients that had received input from microbiologythe prevalence of antimicrobials prescribedthe location of the patient’s home residencepatient/parent willingness to go home on OPAT.The data for patient numbers and bed day savings was then extrapolated to 52 weeks in order to be indicative of one year.ResultsOver the five days, 66 patients were identified that met the exclusion criteria to be referred for OPAT or IVOST. After clinical consideration the consultant deemed 4 patients to be suitable for OPAT and 19 for IVOST and discharge which generated a potential bed day saving of 38 bed days. This was comprised of 17 days through providing IVAs via OPAT and 21 days from timelier IVOST and discharge of patients. Extrapolated to be representative of one year, this would be a bed saving to the Trust of 1, 976 bed days.ConclusionThe potential has been identified for the hospital to make considerable bed day savings through the investment in an extended antimicrobial stewardship programme and establishment of a paediatric OPAT service. A business case has been submitted to the hospital board for consideration, with the hope that the service will be funded for a six month probationary period in order to assess its impact over the winter months, when demand for beds and pressures on PICU and theatres are highest.ReferencesPatel S, et al. 2015. Good practice recommendations for paediatric outpatient parenteral antibiotic therapy (p-OPAT) in the UK: a consensus statement. Journal of Antimicrobial Chemotherapy2015;702:360–373.Carter B, et al. Delivery, setting and outcomes of paediatric outpatient parenteral antimicrobial therapy (OPAT): a scoping review. BMJ Open, 2018;8:e021603.Hodgson KA, et al. The use, appropriateness and outcomes of outpatient parenteral antimicrobial therapy. Archives of Disease in Childhood, 2016:10:886–893.Knackstedt ED, et al. Outpatient parenteral antimicrobial therapy in pediatrics: an opportunity to expand antimicrobial stewardship. Infection Control & Hospital „Epidemiology 2015:36:222–224.

scholarly journals Patient experiences with outpatient parenteral antibiotic therapy: results of a patient survey comparing skilled nursing facilities and home infusion

2019 ◽  
Author(s):  
Omar Mansour ◽  
Alicia I Arbaje ◽  
Jennifer L Townsend
Keyword(s):  
Patient Satisfaction ◽  
Antibiotic Therapy ◽  
Patient Experience ◽  
Patient Experiences ◽  
Skilled Nursing Facilities ◽  
Nursing Facilities ◽  
Skilled Nursing ◽  
Parenteral Antibiotic ◽  
Outpatient Parenteral Antibiotic Therapy ◽  
Home Infusion

Abstract Background Outpatient parenteral antibiotic therapy (OPAT) is prescribed for patients with serious infections requiring prolonged therapy. Most patients requiring OPAT are discharged either home with home healthcare companies (HHCs) or to skilled nursing facilities (SNFs). Few data are available regarding patient experiences in these different sites of care. Objectives (1) Compare overall patient satisfaction with OPAT care across the SNF and HHC settings; (2) Identify barriers to patient satisfaction in OPAT; and (3) Develop a model for OPAT patient satisfaction that can help programs improve the patient experience across both sites of care. Methods We developed and administered a patient experience survey to 100 patients returning to a single clinic for follow up. The survey consisted of 15 items (Likert scale, multiple choice, and free text responses). Patient characteristics and responses to the survey for patients who received care at home and at SNFs were analyzed and compared. Results Of the 100 patients surveyed, 98 completed the survey. Overall, HHC patients were more satisfied with their care than patients in SNFs, with a greater proportion stating they would recommend the site to others (71.7% for HHC and 32.7% for SNFs, p<0.01). Patients in SNFs had a larger number of complaints about lapses in medical care, infection prevention, and the physical environment than HHC patients. Conclusion OPAT patient satisfaction is higher for home infusion than SNFs. In order to improve the patient experience, OPAT programs need to engage stakeholders in HHCs and SNFs to improve communication and care delivery.

scholarly journals First Pediatric Outpatient Parenteral Antibiotic Therapy Clinic in Indonesia

2020 ◽  
Vol 8 ◽  
Author(s):  
Aryono Hendarto ◽  
Nina Dwi Putri ◽  
Dita Rizkya Yunita ◽  
Mariam Efendi ◽  
Ari Prayitno ◽  
...  
Keyword(s):  
Antibiotic Therapy ◽  
Parenteral Antibiotic ◽  
Outpatient Parenteral Antibiotic Therapy ◽  
Therapy Clinic

scholarly journals Risk Factors for Adverse Events in Children Receiving Outpatient Parenteral Antibiotic Therapy

2021 ◽  
Vol 11 (2) ◽  
pp. 153-159
Author(s):  
Elizabeth Townsley ◽  
Jessica Gillon ◽  
Natalia Jimenez-Truque ◽  
Sophie Katz ◽  
Kathryn Garguilo ◽  
...  
Keyword(s):  
Risk Factors ◽  
Adverse Events ◽  
Antibiotic Therapy ◽  
Parenteral Antibiotic ◽  
Outpatient Parenteral Antibiotic Therapy

Survival Times and Complications of Catheters Used for Outpatient Parenteral Antibiotic Therapy in Children

2007 ◽  
Vol 46 (3) ◽  
pp. 247-251 ◽  
Author(s):  
Sabiha Hussain ◽  
Margarita M. Gomez ◽  
Peter Wludyka ◽  
Thomas Chiu ◽  
Mobeen H. Rathore
Keyword(s):  
Antibiotic Therapy ◽  
Survival Times ◽  
Parenteral Antibiotic ◽  
Outpatient Parenteral Antibiotic Therapy

Rethinking Home-based Outpatient Parenteral Antibiotic Therapy for Persons Who Inject Drugs

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Raagini Jawa ◽  
Hallie Rozansky ◽  
Dylan Clemens ◽  
Maura Fagan ◽  
Alexander Y. Walley
Keyword(s):  
Antibiotic Therapy ◽  
Persons Who Inject Drugs ◽  
Parenteral Antibiotic ◽  
Outpatient Parenteral Antibiotic Therapy ◽  
Home Based

scholarly journals Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for Enterococcus faecalis Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs?

2020 ◽  
Vol 65 (1) ◽  
pp. e02099-20
Author(s):  
Laura Herrera-Hidalgo ◽  
Arístides de Alarcón ◽  
Luis Eduardo López-Cortes ◽  
Rafael Luque-Márquez ◽  
Luis Fernando López-Cortes ◽  
...  
Keyword(s):  
Single Dose ◽  
Infective Endocarditis ◽  
Antibiotic Therapy ◽  
Enterococcus Faecalis ◽  
High Dose ◽  
Synergistic Activity ◽  
Parenteral Antibiotic ◽  
Once Daily ◽  
Content Type ◽  
Outpatient Parenteral Antibiotic Therapy

ABSTRACTCeftriaxone administered as once-daily high-dose short infusion combined with ampicillin has been proposed for the treatment of Enterococcus faecalis infective endocarditis in outpatient parenteral antibiotic therapy programs (OPAT). This combination requires synergistic activity, but the attainment of ceftriaxone synergic concentration (Cs) with the regimen proposed for OPAT has not been studied. This phase II pharmacokinetic study enrolled healthy adult volunteers who underwent two sequential treatment phases. During phase A, volunteers received 2 g of ceftriaxone each 12 h during 24 h followed by a 7-day wash-out. Then the participants received phase B, which consisted of a single dose of 4 g of ceftriaxone. Throughout both phases, each volunteer underwent intensive pharmacokinetic (PK) sampling over 24 h. Ceftriaxone total and unbound concentrations were measured. Twelve participants were enrolled and completed both phases. Mean ceftriaxone total and free concentrations 24 h after the administration of 2 g each 12 h were 86.44 ± 25.90 mg/liter and 3.59 ± 1.35 mg/liter, respectively, and after the 4-g single dose were 34.60 ± 11.16 mg/liter and 1.40 ± 0.62 mg/liter, respectively. Only 3 (25%) patients in phase A maintained unbound plasma concentrations superior to the suggested Cs = 5 mg/liter during 24 h, and none (0%) in phase B. No grade 3 to 4 adverse events or laboratory abnormalities were observed. Ceftriaxone optimal exposure combined with ampicillin to achieve maximal synergistic activity against E. faecalis required for the treatment of infective endocarditis remains unknown. However, the administration of a single daily dose of 4 g of ceftriaxone implies a reduction in the time of exposure to the proposed Cs. (This study has been registered in the European Union Drug Regulating Authorities Clinical Trials [EudraCT] database under identifier 2017-003127-29.)

Sign in / Sign up

Export Citation Format

Share Document